Latest News

As Epiduo goes OTC, offering once-daily adapalene+BPO for mild to moderate acne, Heather Woolery-Lloyd, MD, FAAD, gives advice on irritation, purging, and simplifying routines.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can daily supplements "clear skin from within", or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Plant-based oat oil and aloe moisturizer outperforms metronidazole in a 12-week trial, reducing rosacea redness and lesions safely without irritation.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Oral peptide drugs move beyond injections, bringing targeted psoriasis therapy like icotrokinra and reshaping dermatology’s treatment options.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Medicus Pharma advances microneedle doxorubicin therapy to clear multiple Gorlin syndrome BCC lesions.

This review of the latest dermatological studies includes insights on PeakPASI in psoriasis severity, the future of digital derm lectures, negative pressure wound therapy, and more.

New IND pushes QRX003 toward first targeted therapy for peeling skin syndrome, with early pediatric results showing rapid healing and no safety issues.

Discover how oral GliSODin delivers SOD to boost skin defense, enhance retinoids, and reduce UV damage and dark spots—backed by clinical trials.

Unlock hidden dermatology revenue by tracking retention drop-offs, procedure sequencing, and device utilization—before collections reveal the leaks.